

Date and Time: *Friday 18th October 2013, 10:00-16:00*

Minutes: [Draft](#)

Guideline Development Group Meeting 10 Lipid Modification (update)

Place: *Henry Cohen Room, Royal College of Physicians
11 St Andrews Place, London NW1 4LE*

Present:

Anthony Wierzbicki (Chair)	(Present for notes 1 – 9)
Rajai Ahmad (Cardiologist)	(Present for notes 1 – 9)
Lindsay Banks (Pharmacist)	(Present for notes 1 – 9)
Liz Clark (Patient/carer member)	(Present for notes 1 – 9)
Martin Duerden (General practitioner)	(Present for notes 1 – 9)
Dermot Neely (Chemical pathologist and lipidologist)	(Present for notes 1 – 9)
Nadeem Qureshi (General practitioner)	(Present for notes 1 – 9)
Alan Rees (Metabolic/general medicine/elderly care physician)	(Present for notes 1 – 9)
Angela Cooper (Senior research fellow)	(Present for notes 1 – 5)
Martin Harker (Heath economist)	(Present for notes 1 – 9)
Norma O’Flynn (Clinical director)	(Present for notes 1 – 9)
Silvia Rabar (Senior project manager and research fellow)	(Present for notes 1 – 9)
David Wonderling (Heath economics lead)	(Present for notes 7 – 9)

In attendance:

NICE Staff:		
Lyn Knott	(Senior medical editor)	(Present for notes 1 – 9)

Observers:

--	--	--

Notes

1. The Chair welcomed the group to the tenth meeting of this GDG. Apologies were received from Eleanor Grey, Michael Khan, Emma McGowan, Caroline Keir, and Lina Gulhane. The Chair asked all GDG members to declare any relevant conflicts of interest. The following interests were declared:
 - 1.1. Alan Rees
Non-personal pecuniary interest: I have acted as a paid member of an Advisory Board for Novartis who are developing a drug from chylomicronemia syndrome (not available at present and no relevance to the current NICE guidelines), and to Amgen who are developing a monoclonal antibody to PCSK9 but is not licensed at present. I have been asked to speak at a forthcoming meeting on diabetes which is sponsored by AstraZeneca but I am not promoting drug or any medication. I am principle investigator to two trials involving monoclonal antibody to PCSK9 and an antisense oligonucleotide to Apo B. I have recently given lectures to the Young Diabetes Forum and to a day long conference at the RSM on New Drugs in Development for the Treatment of Dyslipidaemia. None of these drugs are in clinical use or licensed at present. I have also sat on an advisory board organised and funded by Aegerion who are developing a drug for homozygous familial hypercholesterolemia Lomitapide.
 - 1.2. Dermot Neely
Personal non-pecuniary interest: I have accepted an invitation from AMGEN to attend an advisory board on 5th November 2013 to discuss the development of a novel therapy for Familial Hypercholesterolaemia and I will deliver a short presentation on current management of severe FH. I will not accept reimbursement for this, the honorarium will be paid directly to HEART UK charity.
2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
3. An update was then given to the GDG on progress since the last meeting.
4. The Chair introduced Lyn Knott, senior medical editor at NCGC, who gave presentation on Role of the NICE editor in guideline development.
The Chair thanked Lyn Knott for her presentation.
5. The Chair introduced Angela Cooper, senior research fellow at NCGC, Silvia Rabar, senior project manager and research fellow at NCGC, and Martin Harker, health economist at NCGC, who gave a presentation on the updated reviews on Anion exchange resins, Fibrates, Nicotinic acids and Omega-3 fatty acids.
The GDG then discussed the evidence presented in relation to this guideline and reviewed the draft recommendations. The Chair thanked Angela Cooper, Silvia Rabar and Martin Harker for their presentation.
6. Review of recommendations: The GDG reviewed all the recommendations that had been drafted so far to make sure they are in line with the evidence and to clarify the wording.
7. The Chair introduced Martin Harker, health economist at NCGC, who gave a presentation on the outline of the health economic model. The GDG discussed and agreed the assumptions for the model.
The Chair thanked Martin Harker for his presentation.
8. The Chair introduced Norma O'Flynn, clinical director at NCGC, who gave a presentation on the research recommendations. The GDG agreed to the topics for the research recommendations.

Notes

The Chair thanked Norma O'Flynn for her presentation.

- 9 There were no other businesses to discuss.
The Chair closed the meeting and thanked everybody for attending.

Date, time and venue of the next meeting:

22 November 2013, 10:00-16:00, at the National Clinical Guideline Centre, Boardroom,
180 Great Portland Street, London W1W 5QZ